Skip to main content
Premium Trial:

Request an Annual Quote

Curetis Launches Subsidiary Ares Genetics for Antibiotic Resistance Testing

NEW YORK (GenomeWeb) – Molecular diagnostics firm Curetis has established a wholly owned subsidiary Ares Genetics that will focus on developing antibiotic resistance tests, the company said this week.

Ares Genetics, headquartered in Vienna, Austria, will harness the Genetic Antibiotic Resistance and Susceptibility Database (GEAR) that Curetis recently acquired from Siemens to understand the genetic basis for antibiotic resistance.

The new firm will be headed by Andreas Posch, who joined Curetis in March from Siemens, where he was head of bioinformatics and responsible for GEAR. Achim Plum, chief commercial officer at Curetis, will also serve as managing director of Ares.

Ares plans to use the GEAR database, which contains DNA sequences of more than 11,000 bacterial strains and related sensitivity data for 21 antibiotics, to identify biomarkers and biomarker combinations that predict antibiotic resistance, as well as potential new targets for antimicrobial drugs.

"GEAR will expand Curetis' content leadership with novel antibiotic resistance markers and form the basis for additional business, including clinical decision support, pharma research, or next-generation sequencing interpretation services," Posch said in a statement. "Our goal is to advance GEAR as a collaborative research platform for academic and translational research, public health, and industry partners."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more